TY - JOUR
T1 - Thymoma and thymic carcinomas
AU - Scorsetti, Marta
AU - Leo, Francesco
AU - Trama, Annalisa
AU - D'Angelillo, Rolando
AU - Serpico, Danila
AU - Macerelli, Marianna
AU - Zucali, Paolo
AU - Gatta, Gemma
AU - Garassino, Marina Chiara
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Thymomas Ts and thymic carcinomas TCs are rare tumours of the mediastinum with an incidence rate of 1.7/million per year in Europe.Histological classification is based on rate of non-malignant-appearing thymic epithelial cells and proportions of lymphocytes A, AB, B1, B2, B3, and C, while staging system concerns localisation of the involved areas.Surgery is the mainstay of treatment with a 10-year survival of 80%, 78%, 75%, and 42% for stages I, II, III and IV, respectively, with an R0 resection.Radiotherapy has a role in selected cases stage III patients or R1-2 residual and platinum-based chemotherapy remains the standard of care for patients with advanced disease.A multimodality approach would be advisable when surgery is not recommended. Since molecular aberrations are poorly understood and few responses are reported, targeted therapies are yet being studied.In this review, we describe key aspects of clinical management for Ts and TCs.
AB - Thymomas Ts and thymic carcinomas TCs are rare tumours of the mediastinum with an incidence rate of 1.7/million per year in Europe.Histological classification is based on rate of non-malignant-appearing thymic epithelial cells and proportions of lymphocytes A, AB, B1, B2, B3, and C, while staging system concerns localisation of the involved areas.Surgery is the mainstay of treatment with a 10-year survival of 80%, 78%, 75%, and 42% for stages I, II, III and IV, respectively, with an R0 resection.Radiotherapy has a role in selected cases stage III patients or R1-2 residual and platinum-based chemotherapy remains the standard of care for patients with advanced disease.A multimodality approach would be advisable when surgery is not recommended. Since molecular aberrations are poorly understood and few responses are reported, targeted therapies are yet being studied.In this review, we describe key aspects of clinical management for Ts and TCs.
KW - Chemotherapy
KW - Diagnosis
KW - Radiotherapy
KW - Surgery
KW - Targeted therapies
KW - Thymic carcinoma
KW - Thymomas
UR - http://www.scopus.com/inward/record.url?scp=84959457888&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959457888&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2016.01.012
DO - 10.1016/j.critrevonc.2016.01.012
M3 - Article
AN - SCOPUS:84959457888
VL - 99
SP - 332
EP - 350
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
ER -